CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题：Advances in immunotherapy for mucosal melanoma: harnessing immune checkpoint inhibitors for improved treatment outcomes.
Advances in immunotherapy for mucosal melanoma: harnessing immune checkpoint inhibitors for improved treatment outcomes.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
黏膜黑色素瘤（MM）由于其侵袭性和有限的治疗选择，构成了重大的临床挑战。近年来，免疫治疗已成为MM的一种有前景的策略，尤其关注PD-1和CTLA-4抑制剂等免疫检查点抑制剂。这些抑制剂通过利用机体对肿瘤的免疫反应，已显示出显著疗效。此外，过继细胞转移（ACT）、抗血管生成治疗和联合治疗因其在MM治疗中的潜力而受到关注。ACT涉及改造T细胞以靶向黑色素瘤细胞，显示出有前景的抗肿瘤活性。抗血管生成治疗旨在通过抑制血管生成来阻碍肿瘤生长，而联合治疗，包括免疫检查点抑制剂和靶向治疗，提供了多方面的策略以克服治疗耐药性。这篇综合性综述探讨了MM免疫治疗的进展，强调了多种治疗模式在提高治疗结局和应对这种侵袭性恶性肿瘤所带来的挑战中的作用。
Mucosal melanoma (MM) poses a significant clinical challenge due to its aggressive nature and limited treatment options. In recent years, immunotherapy has emerged as a promising strategy for MM, with a particular focus on immune checkpoint inhibitors such as PD-1 and CTLA-4 inhibitors. These inhibitors have demonstrated substantial efficacy by harnessing the body's immune response against tumors.
Moreover, adoptive cell transfer (ACT), anti-angiogenic therapy, and combination therapies have garnered attention for their potential in MM treatment. ACT involves modifying T cells to target melanoma cells, showing promising antitumor activity.
Anti-angiogenic therapy aims to impede tumor growth by inhibiting angiogenesis, while combination therapies, including immune checkpoint inhibitors and targeted therapies, offer a multifaceted approach to overcome treatment resistance. This comprehensive review explores the advancements in immunotherapy for MM, highlighting the role of diverse therapeutic modalities in enhancing treatment outcomes and addressing the challenges posed by this aggressive malignancy.
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。
